Ars Technica

Recursion or while loops: Which is better?

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.
Nasdaq

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
GEN

The Netflix of Digital Biology? Recursion Is Reimagining Drug Discovery

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

Forget Recursion Pharmaceuticals stock. This is a much better buy.

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.
Seeking Alpha

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka ...
GEN

Recursion’s Ambitions: Developing 100+ Candidates, Joining with Exscientia

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...